Reneo Pharmaceuticals Inc RPHM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
1.76UNCH (UNCH)
Volume
2,769
Close
1.76quote price arrow down-0.01 (-0.56%)
Volume
73,621
52 week range
0.98 - 11.30
Loading...
  • Open1.78
  • Day High1.78
  • Day Low1.70
  • Prev Close1.77
  • 52 Week High11.30
  • 52 Week High Date04/21/23
  • 52 Week Low0.98
  • 52 Week Low Date12/14/23

Key Stats

  • Market Cap58.821M
  • Shares Out33.42M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.24
  • YTD % Change10

KEY STATS

  • Open1.78
  • Day High1.78
  • Day Low1.70
  • Prev Close1.77
  • 52 Week High11.30
  • 52 Week High Date04/21/23
  • 52 Week Low0.98
  • 52 Week Low Date12/14/23
  • Market Cap58.821M
  • Shares Out33.42M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.24
  • YTD % Change10

RATIOS/PROFITABILITY

  • EPS (TTM)-2.52
  • P/E (TTM)-0.70
  • Fwd P/E (NTM)-1.26
  • EBITDA (TTM)-82.886M
  • ROE (TTM)-82.07%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Reneo Pharmaceuticals Inc

 

Profile

MORE
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in...
Michael Grey
Executive Chairman of the Board
Gregory Flesher
President, Chief Executive Officer, Director
Michael Cruse
Chief Operating Officer
Address
18575 Jamboree Road, Suite 275-S
Irvine, CA
92612
United States

Top Peers

SYMBOLLASTCHG%CHG
AVRO
AVROBIO Inc
1.24+0.02+1.64%
IMRX
Immuneering Corp
1.77-0.09-4.84%
NXTC
NextCure Inc
1.57+0.06+3.97%
VNRX
VolitionRX Ltd
0.6172+0.0231+3.8882%
GANX
Gain Therapeutics Inc
3.15-0.03-0.94%